Akums Drugs And Pharmaceuticals Limited · NSE:AKUMS
Akums Drugs And Pharmaceuticals — Investor Presentation (February 2025)
21 slides from Akums Drugs And Pharmaceuticals's investor presentation, Feb 11, 2025
Slide 1: Intimation of Schedule of Analysts/Investor Meet
Ref: Akums/Exchange/2024-25/64 February 11, 2025 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, C-1, Block G, Rotunda Building, Phiroze Jeejeebhoy Bandra Kurla Complex, Towers, Dalal Street, Fort, Mumbai – Bandra (E),Mumbai – 40
Slide 2: Investor Presentation February 2025
Investor Presentation February 2025
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Akums Drugs and Pharmaceuticals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscr
Slide 4: Managing Directors' Message
Managing Directors’ Message We take pleasure in declaring the Q3 results of the company and thank all the stakeholders and shareholders for there continued support to the company. Q3 was an exciting quarter for the company. With our focus on establishing Akums' global CDMO footprint, we took a signi
Slide 5: Q3 and 9M FY24-25 Financial Performance Highlights
Q3 and 9M FY24-25 Financial Performance Highlights
Slide 6: Consolidated Quarterly Performance Highlights (1/2)
Consolidated Quarterly Performance Highlights (1/2) Total Income (INR Mn) Adjusted EBITDA1 (INR Mn) Adjusted PAT2 (INR Mn) Margin 12.7% 12.9% 13.3% Margin 5.6% 6.4% 6.5% % % 10,466 10,257 10,250 667 663 1,347 1,359 1,307 573 Q1 FY 25 Q2 FY 25 Q3 FY 25 Q1 FY 25 Q2 FY 25 Q3 FY 25 Q1 FY 25 Q2 FY 25 Q3
Slide 7: Consolidated Quarterly Performance Highlights (2/2)
Consolidated Quarterly Performance Highlights (2/2) Total Income (INR Mn) Adjusted EBITDA1 (INR Mn) Margin 11.1% 13.3% % 10,918 10,250 1,359 1,212 Q3 FY 24 Q3 FY 25 Q3 FY 24 Q3 FY 25 Adjusted PAT2 (INR Mn) Margin 5.3% 6.5% % 663 575 Q3 FY 24 Q3 FY 25 (1) Adjusted EBITDA = Profit before tax + fair va
Slide 8: Consolidated 9M FY25 Performance Highlights
Consolidated 9M FY25 Performance Highlights Total Income (INR Mn) Adjusted EBITDA1 (INR Mn) Margin 12.8% 13.0% % 32,578 30,972 4,163 4,013 9m FY 24 9m FY 25 9m FY 24 9m FY 25 Adjusted PAT2 (INR Mn) Margin 5.4% 6.1% % 1,903 1,745 9m FY 24 9m FY 25 (1) Adjusted EBITDA = Profit before tax + fair value
Slide 9: Segmental Financials
Segmental Financials CDMO1 (INR Mn) Branded and Generic Formulations (INR Mn) API1 (INR Mn) Margin % Margin % Margin % 13.0% 15.4% 13.8% 10.8% -29.9% -27.2% 1,735 1,829 8,542 7,874 552 401 1,111 1,214 239 198 Revenue EBITDA Revenue EBITDA Revenue EBITDA (109) (165) Q3 FY24 Q3 FY25 Q3 FY24 Q3 FY25 Q3
Slide 10: Quarterly Updates
Quarterly Updates • Signed Euro 200 million contract for supply of oral liquid formulation, intended to be sold in Europe CDMO contract for • Euro 100 million to be received as upfront consideration; rest over the course of the contract European markets • 8-year contract till 2032; supply to commenc
Slide 11: Summary Profit and Loss Statement
Summary Profit and Loss Statement P/L (Rs Mn) Q3 FY 25 Q2 FY 25 Q3 FY 24 9m FY 25 9m FY 24 Revenue 10,104 10,331 10,828 30,626 32,340 Other Income 146 135 89 346 238 Total income 10,250 10,466 10,918 30,972 32,578 COGS 6,024 5,960 6,857 17,943 19,809 Employee Cost 1,756 1,801 1,625 5,319 4,829 Other
Slide 12: Summary Segmental Statement
Summary Segmental Statement Segmental (Rs Mn) Q3 FY 25 Q2 FY 25 Q3 FY 24 9m FY 25 9m FY 24 CDMO Revenue 7,874 7,987 8,542 23,681 25,348 EBITDA 1,214 1,227 1,111 3,652 4,062 EBITDA Margin 15.4% 15.4% 13.0% 15.4% 16.0% Branded and Generic Formulation Revenue 1,829 1,750 1,735 5,253 5,507 EBITDA 198 18
Slide 13: IPO proceeds utilization
IPO proceeds utilization The Company successfully got listed on 6 August 2024. Post listing, the Company received Rs. 6,373.70 million (net of offer expenses borne by Company) to be spent as mentioned. Amount Amount Utilised Remaining Amount Purpose of Funds (in million) (in million) (in million) Lo
Slide 14: India's Largest CDMO
Akums has a strategic presence across the pharmaceutical value chain driven by large R&D and manufacturing capabilities which reflects in the diverse and longstanding client relationships. 4,959 Cr 4,146 1,524 220+ (49.6bn) units Commercialized Customers; serving Innovative CDMO Mfg. formulations ac
Slide 15: Two Decades' Legacy of Expertise, Experience and Trust
Two Decades’ Legacy of Expertise, Experience and Trust 2004–2010 ` 2010–2021 2021 – 2024 Build Strengthen Accelerate • Incorporated in April 2004 • Dedicated facilities for Hormones, • In Nov 2019, Quadria Capital(3) • Set up of first plant for oral Cosmetics and Dermatology bought a minority stake
Slide 16: Akums has a right to win in a large pharma opportunity
Akums has a right to win in a large pharma opportunity 1 Largest India Focused CDMO with diverse client base 2 Comprehensive Offerings With Advanced Manufacturing Capabilities 3 Large and Growing R&D Capabilities Across Product Portfolio 4 Strategic Presence Across the Pharmaceutical Value Chain 5 E
Slide 17: Largest India Focused CDMO with diverse client base
1 Largest India Focused CDMO1 with diverse client base 10.0% share by value in 30.2% share in Indian 4,000+ 60+ 18,500+ total addressable Indian Domestic CDMO market in Formulations Dosage Forms SKUs manufactured in FY24 domestic CDMO in FY242 FY24 by value2 Significant base of CDMO Clients… .. with
Slide 18: Technologically Advanced Manufacturing Capabilities
2 Technologically Advanced Manufacturing Capabilities Annual Capacity Location Year Dosage Forms Key Accreditations1 (Cr units) 1 Haridwar 2004 649 Oral Solids 2 Haridwar 2007 15 Oral Liquids 3 Haridwar 2007 39 Sterile Preparations 4 Hormonal – Oral, Injectables and Haridwar 2010 244 Topicals 5 Hari
Slide 19: Extensive R&D Capabilities Across Product Portfolio
3 Extensive R&D Capabilities Across Product Portfolio R&D Capabilities Innovative In-house Technologies 4 R&D Centers across formulations and API, 2 DSIR approved1 R&D scientists with 300+ doctorates 406 and post-graduates1 DCGI approvals1, along with 925+ 923 FSSAI approvals Patent applications fil
Slide 20: Strategic Presence Across the Pharmaceutical Value Chain
4 Strategic Presence Across the Pharmaceutical Value Chain In addition to the CDMO Business, Akums is also engaged in manufacturing and sale of Branded Formulations, Trade Generics and APIs across domestic and overseas market Domestic Branded Formulations Exports Oriented Branded Formulations Dossie
Slide 21: Slide 21
Akums Drugs and Pharmaceuticals — Investor Presentation (February 2025) on 6ix